A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 27-34

  Ahokoski, O ^a   Irjala, K ^a   Huhtala, S ^b   Salminen, E ^a   Scheinin, H ^a   Huupponen, R ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Aromatase inhibitor; MPV 2213ad; Phase I study

Indexed keywords

4 [3 (4 FLUOROPHENYL) 2 HYDROXY 1 (1,2,4 TRIAZOL 1,1 YL)PROPYL]BENZONITRILE; ALDOSTERONE; AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; ESTRADIOL; FADROZOLE; FINROZOLE; FOLLITROPIN; HYDROCORTISONE; LETROZOLE; LUTEINIZING HORMONE; PLACEBO; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ALDOSTERONE BLOOD LEVEL; ANXIETY; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; AROMATASE INHIBITORS; BINDING, COMPETITIVE; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; HORMONES; HUMANS; MALE; MICROSCOPY, ELECTRON, SCANNING; NITRILES; PLACEBOS; TRIAZOLES; URINALYSIS;

EID: 0033003860     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050588     Document Type: Article

References (29)

1. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA (1982) Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 96: 94-101
2. Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M, Carpi A, Di Costanzo F, Franciosi V, Gori S, Indelli M, Passalacqua R (1992) Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol 10: 984-989
3. Nemoto T, Rosner D, Patel JK, Dao TL (1989) Aminoglutethimide in patients with metastatic breast cancer. Cancer 63: 1673-1675
4. Lönning PE, Kvinnsland S (1988) Mechanism of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35: 685-710
5. Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ (1994) Hormonal treatment for metastatic breast cancer. Cancer 73: 354-361
6. Samonis G, Margioris AN, Bafaloukos D, Razis DV (1994) Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG + MPA in generalized breast cancer. Oncology 51:411-415
7. Dexter RN, Fishman LM, Ney RL, Liddle GW (1967) Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies on the mechamism of action. J Clin Endocrinol Metab 27: 473-480
8. Manni A, Santen RJ (1988) Clinical use of aromatase inhibitors in the treatment of breast cancer. In: Osborne CK (ed) Endocrine therapies in breast and prostate cancer. Kluwer Academic Publishers, Boston, pp 67-81
9. Glauber JG, Kiang DT (1992) The changing role of hormonal therapy in advanced breast cancer. Semin Oncol 19: 308-316
10. Santen RJ (1990) Clinical use of aromatase inhibitors: current data and future perspectives. J Enzym Inhib 4: 79-99
11. Lönning PE, Dowsett M, Powles TJ (1990) Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35: 355-366
12. Ahokoski O, Irjala K, Huupponen R, Halonen K, Salminen E, Scheinin H (1998) Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study. Br J Clin Pharmacol 45: 141-146
13. Goldman J, Wajchenberg BL, Liberman B, Nery M, Achando S, Germek OA (1985) Contrast analysis for the evaluation of the circadian rhythms of plasma cortisol, androstenedione, and testosterone in normal men and the possible influence of meals. J Clin Endocrinol Metab 60: 164-167
14. Lejeune-Lenain C, Van Cauter E, Desir D, Beyloos M, Franckson JRM (1987) Control of circadian and episodic variations of adrenal androgen secretion in man. J Endocrinol Invest 10: 267-276
15. Nankin HR, Pinto R, Fan D-F, Troen P (1975) Daytime titers of testosterone, LH, estrone, estradiol and testosterone-binding protein: acute effects of LH and LH-releasing hormone in men. J Clin Endocrinol Metab 41: 271-281
16. Dowsett M (1990) Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J Steroid Biochem Mol Biol 37: 1037-1041
17. Perez Carrion R, Alberola Candel V, Calabresi F, Michel RTh, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M, Pannuti F, van Belle S, Martinez J, Wehrle E, Royce CM (1994) Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5 [Suppl. 7]: S19-24
18. Bonnefoi HR, Smith IE, Dowsett M, Trunet PF, Houston SJ, da Luz RJ, Rubens RD, Coombes RC, Powles TJ (1996) Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br J Cancer 73: 539-542
19. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J (1996) Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double-blind controlled multi-institutional trials. Cancer 77: 2503-2513
20. Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G (1993) Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab 77: 319-323
21. Plourde PV, Dyroff M, Dukes M (1994) Arimidex®: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30: 103-111
22. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A: 404-412
23. Buzdar A, Jonat W, Howell A, Jones E, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde P (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14: 2000-2011
24. Santen RJ, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11: 221-265
25. Bhatnagar AS, Mueller P, Schenkel L, Trunet PF, Beh I, Schieweck K (1992) Inhibition of estrogen biosynthesis and its consequences on gonadotropin secretion in the male. J Steroid Biochem Mol Biol 41: 437-443
26. Perez N, Borja J (1992) Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer. J Int Med Res 20: 303-312
27. Trunet PF, Mueller P, Girard F, Aupetit B, Bhaynagar S, Zognbi F, Ezzet F, Menard J (1993) The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab 74: 571-576
28. Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers M, Santen RJ, Santner SJ (1994) Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 33: 19-26
29. Goss PE, Gwyn KMEH (1994) Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 12: 2460-2470